Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hadj Tahar

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Issues in Emerging Health Technologies|December 23, 2004
Bevacizumab for advanced colorectal cancerA Hadj Tahar
Issues in Emerging Health Technologies|April 6, 2005
Alemtuzumab for B-cell chronic lymphocytic leukemiaA Hadj Tahar
Issues in Emerging Health Technologies|April 6, 2005
Pregabalin for peripheral neuropathic painA Hadj Tahar
Issues in Emerging Health Technologies|October 1, 2004
Omalizumab as add-on therapy to inhaled steroids for asthmaA Hadj Tahar
Behavioural Pharmacology|March 16, 2005
Effect of amantadine on motor memory consolidation in humansA Hadj Tahar, P J Blanchet, J Doyon
Clinical Neuropharmacology|October 6, 2000
Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeysA Hadj Tahar, L Grégoire, E Bangassoro, et al.
European Journal of Pharmacology|July 8, 2000
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeysA Hadj Tahar, N Bélanger, E Bangassoro, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 24, 2000
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeysR Grondin, A Hadj Tahar, V D Doan, et al.
Revue Neurologique|February 24, 2004
[Pathophysiology and therapy of L-Dopa-induced dyskinesia]A Hadj Tahar, E Bézard, R Grondin, et al.
Clinical Neuropharmacology|October 12, 1999
Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeysV D Doan, R Grondin, A Hadj Tahar, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Issues in Emerging Health Technologies|December 23, 2004
Bevacizumab for advanced colorectal cancerA Hadj Tahar
Issues in Emerging Health Technologies|April 6, 2005
Alemtuzumab for B-cell chronic lymphocytic leukemiaA Hadj Tahar
Issues in Emerging Health Technologies|April 6, 2005
Pregabalin for peripheral neuropathic painA Hadj Tahar
Issues in Emerging Health Technologies|October 1, 2004
Omalizumab as add-on therapy to inhaled steroids for asthmaA Hadj Tahar
Behavioural Pharmacology|March 16, 2005
Effect of amantadine on motor memory consolidation in humansA Hadj Tahar, P J Blanchet, J Doyon
Clinical Neuropharmacology|October 6, 2000
Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeysA Hadj Tahar, L Grégoire, E Bangassoro, et al.
European Journal of Pharmacology|July 8, 2000
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeysA Hadj Tahar, N Bélanger, E Bangassoro, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|February 24, 2000
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeysR Grondin, A Hadj Tahar, V D Doan, et al.
Revue Neurologique|February 24, 2004
[Pathophysiology and therapy of L-Dopa-induced dyskinesia]A Hadj Tahar, E Bézard, R Grondin, et al.
Clinical Neuropharmacology|October 12, 1999
Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeysV D Doan, R Grondin, A Hadj Tahar, et al.
Pageof 2